Literature DB >> 11825571

Effects of sequence and structure on the hypermutability of immunoglobulin genes.

Nancy Michael1, Terence E Martin, Dan Nicolae, Nayun Kim, Kris Padjen, Ping Zhan, Hanh Nguyen, Carl Pinkert, Ursula Storb.   

Abstract

Somatic hypermutation (SHM) is investigated in related immunoglobulin transgenes that differ in a short artificial sequence designed to vary the content of hotspot motifs and the potential to form RNA or DNA secondary structures. Mutability depends on hotspots, not secondary structure. Hotspot motifs predict about 50% of the mutations; the rest are in neutral and coldspots. Clusters of mutations and the sequential addition of mutations found in cell pedigrees suggest epigenetic attributes of SHM. Sometime in SHM, an essential factor seems to become limiting. Particular error-prone DNA polymerases appear to create mutations in hotspots on the top and bottom DNA strands throughout the target and the SHM process. One transgene is superhypermutable in all regions, suggesting the presence of a cis-element that enhances SHM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11825571     DOI: 10.1016/s1074-7613(02)00261-3

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  27 in total

1.  Correlation of somatic hypermutation specificity and A-T base pair substitution errors by DNA polymerase eta during copying of a mouse immunoglobulin kappa light chain transgene.

Authors:  Youri I Pavlov; Igor B Rogozin; Alexey P Galkin; Anna Y Aksenova; Fumio Hanaoka; Christina Rada; Thomas A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

2.  Somatic hypermutation of the AID transgene in B and non-B cells.

Authors:  Alberto Martin; Matthew D Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-29       Impact factor: 11.205

Review 3.  Combinatorial mechanisms regulating AID-dependent DNA deamination: interacting proteins and post-translational modifications.

Authors:  Bao Q Vuong; Jayanta Chaudhuri
Journal:  Semin Immunol       Date:  2012-07-06       Impact factor: 11.130

4.  Phylogenetic fate mapping.

Authors:  Stephen J Salipante; Marshall S Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-28       Impact factor: 11.205

5.  Reconsidering the human immunoglobulin heavy-chain locus: 1. An evaluation of the expressed human IGHD gene repertoire.

Authors:  C E H Lee; B Gaëta; H R Malming; M E Bain; W A Sewell; A M Collins
Journal:  Immunogenetics       Date:  2006-01-10       Impact factor: 2.846

Review 6.  Evaluation of molecular models for the affinity maturation of antibodies: roles of cytosine deamination by AID and DNA repair.

Authors:  Mala Samaranayake; Janusz M Bujnicki; Michael Carpenter; Ashok S Bhagwat
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

7.  Biased dA/dT somatic hypermutation as regulated by the heavy chain intronic iEmu enhancer and 3'Ealpha enhancers in human lymphoblastoid B cells.

Authors:  Atsumasa Komori; Zhenming Xu; Xiaoping Wu; Hong Zan; Paolo Casali
Journal:  Mol Immunol       Date:  2006-01-10       Impact factor: 4.407

8.  Activation-induced cytidine deaminase (AID) can target both DNA strands when the DNA is supercoiled.

Authors:  Hong Ming Shen; Ursula Storb
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-24       Impact factor: 11.205

9.  V-region mutation in vitro, in vivo, and in silico reveal the importance of the enzymatic properties of AID and the sequence environment.

Authors:  Thomas MacCarthy; Susan L Kalis; Sergio Roa; Phuong Pham; Myron F Goodman; Matthew D Scharff; Aviv Bergman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

10.  The activation-induced cytidine deaminase (AID) efficiently targets DNA in nucleosomes but only during transcription.

Authors:  Hong Ming Shen; Michael G Poirier; Michael J Allen; Justin North; Ratnesh Lal; Jonathan Widom; Ursula Storb
Journal:  J Exp Med       Date:  2009-04-20       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.